This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rinker-Schaeffer, C.W., Partin, A.W., Isaacs, W.B., Coffey, D.S. & Isaacs, J.T. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25, 249–265 (1994).
Dalai, B.I., Keown, P.A. & Greenberg, A.H. Im-munocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. 143, 381–389 (1993).
Truong, L.D. et al. Association of transforming growth factor-β1 with prostate cancer: An im-munohistochemical study. Hum. Pathol. 24, 4–9 (1993).
Smith, J.A. Jr & Scaletsky, R. Future directions in tumor marker technology for prostate cancer. Urol. Clin. North Am. 20, 771–777 (1993).
Thompson, T.C. Growth factors and oncogenes in prostate cancer. Cancer Cells 2, 345–354 (1990).
Merz, V.W. et al. Elevated transforming growth factor-β1 and b3 mRNA levels are associated with ras+ and myc− induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Molec. Endocrinol. 5, 503–513 (1991).
Steiner, M.S. & Barrack, E.R. Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro . Molec. Endocrinol. 6, 15–25 (1992).
Ikeda, T., Lioubin, M.N. & Marquardt, H. Human transforming growth factor type b2: Production by a prostatic adenocarcinoma cell line, purification and initial characterization. Biochemistry 26, 2406–2410 (1987).
Shirai, Y. et al. Elevated levels of plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Jap. J. Cancer Res. 83, 676–679 (1992).
Carter, H.B., Piantadosi, S. & Isaacs, J.I. Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol. 143, 742–746 (1990).
Nishiya, M., Miller, G.J., Lookner, D.H. & Craw-ford, E.D. Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer 74, 3002–3009 (1994).
Thompson, T.C. et al. Transforming growth factor β1 as a biomarker for prostate cancer. J. cell. Biochem. 16, H, 54–61 (1992).
Goldstein, D., O'Leary, M. & Mitchen, J. Effects of interferon beta and transforming growth factor beta on prostatic cell lines. J. Urol. 146, 1173–1177, (1991).
Welch, D.R., Fabra, A. & Nakajima, M. Transforming growth factor β1 stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. natn. Acad. Sci. U.S.A. 87, 7678–7682 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ivanovic, V., Melman, A., Davis-Joseph, B. et al. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1, 282–284 (1995). https://doi.org/10.1038/nm0495-282
Issue Date:
DOI: https://doi.org/10.1038/nm0495-282
This article is cited by
-
TGF-β1 mediates the radiation response of prostate cancer
Journal of Molecular Medicine (2015)
-
Investigation of Soluble HER2 and Transforming Growth Factor Beta-1 Serum Levels in Gestational Trophoblastic Disease
Pathology & Oncology Research (2009)
-
TGF-β may be complimentary to PSA in Chinese prostate cancer
The Chinese-German Journal of Clinical Oncology (2009)
-
Sustained TGFβ exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis
Oncogene (2008)